A Peptide Fragment Called MR-proADM Shows Promise for Diagnosing and Predicting Sepsis Outcomes

The authors conducted a narrative review by searching PubMed, Web of Science, and The Cochrane Library for studies on MR-proADM in sepsis. They included 22 studies, one opinion paper, and one review paper. No exclusion criteria for age, sex, ICU admission, or comorbidities were applied. The review examined both diagnostic and prognostic performance across general sepsis populations and specific subgroups.

Sepsis kills millions worldwide each year, and early detection remains one of the biggest challenges in critical care medicine. Finding a reliable blood-based biomarker that can both diagnose sepsis early and predict who is most likely to deteriorate could save lives by enabling faster, more targeted treatment. MR-proADM — a stable fragment of the peptide adrenomedullin — appears to fill this role better than many existing biomarkers.

The search for reliable sepsis biomarkers has been ongoing for decades. Procalcitonin and C-reactive protein are widely used but imperfect. MR-proADM represents a peptide-based approach that may outperform these conventional markers, particularly for prognosis and monitoring disease progression. As precision medicine advances, combining MR-proADM with other biomarkers and clinical scores could create more accurate risk stratification tools for critically ill patients.

This is a narrative review, not a systematic review or meta-analysis, so it lacks rigorous quality assessment of included studies. No randomized controlled trials were available. The included studies varied in design, patient populations, and measurement methods. The authors acknowledge that larger prospective studies and RCTs are still needed to confirm these findings.